Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
By Dr. Matthew Watson
Regulated Information - Denominator
Read the original here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Dr. Matthew Watson
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Link:
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Dr. Matthew Watson
MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,500 shares of its common stock to nine newly-hired employees, with a grant date of January 18, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
Go here to see the original:
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
By Dr. Matthew Watson
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement
Read the rest here:
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
By Dr. Matthew Watson
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
By Dr. Matthew Watson
– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –
See the original post here:
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic … – Nature.com
By daniellenierenberg
View original post here:
Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic ... - Nature.com
Donating Bone Marrow and Stem Cells: The Process and What To Expect – On Cancer – Memorial Sloan Kettering
By daniellenierenberg
Donating Bone Marrow and Stem Cells: The Process and What To Expect On Cancer - Memorial Sloan Kettering
Follow this link:
Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering
No, Rep. Steve Scalise Didn’t Vote Against Stem Cell Research From Which He Is Now Benefiting – Yahoo News
By daniellenierenberg
No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting Yahoo News
Read more here:
No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - Yahoo News
Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates … – PR Newswire
By daniellenierenberg
Read the original here:
Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates ... - PR Newswire
The Key to Creating Blood Stem Cells May Lie in Your Own Blood – ScienceAlert
By daniellenierenberg
The Key to Creating Blood Stem Cells May Lie in Your Own Blood ScienceAlert
Originally posted here:
The Key to Creating Blood Stem Cells May Lie in Your Own Blood - ScienceAlert
Life-saving donation from Philly athlete saves life: ‘Feeling so strong, I owe that all to him’ – AOL
By daniellenierenberg
Life-saving donation from Philly athlete saves life: 'Feeling so strong, I owe that all to him' AOL
Read more here:
Life-saving donation from Philly athlete saves life: 'Feeling so strong, I owe that all to him' - AOL
Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL – OncLive
By daniellenierenberg
Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL OncLive
The rest is here:
Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL - OncLive
COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures – Medriva
By daniellenierenberg
COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures Medriva
Go here to read the rest:
COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures - Medriva
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31…
By Dr. Matthew Watson
ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 11 JANUARY 2024 at 14.15 EET
Continue reading here:
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31...
QIAGEN N.V. to release results for Q4 2023 and hold webcast
By Dr. Matthew Watson
Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.
Read the rest here:
QIAGEN N.V. to release results for Q4 2023 and hold webcast
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
By Dr. Matthew Watson
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024. TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, January 16, 2024, under the current trading symbol, “RNAZ.” The reverse stock split was approved by TransCode’s stockholders on January 8, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
See the article here:
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries
By Dr. Matthew Watson
DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients.
See the article here:
Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
By Dr. Matthew Watson
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on Thursday, January 18, 2024 at 10:00 a.m. EST.
Follow this link:
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
By Dr. Matthew Watson
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:00 p.m. EST.
See the original post:
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference